AMO Pharma Reports Long-Term Safety Data from REACHCDM-X Study of AMO-02 in Treatment of Congenital Myotonic Dystrophy Type 1

-Four years of study data highlight continued favorable safety profile for AMO-02 -FDA meeting planned in Q4 2025 to discuss potential route to NDA submission for congenital myotonic dystrophy LONDON, Sept. 15, 2025 /PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held...